Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SVG301 (SoVarGen)
- Development stage
- Preclinical
- Lead developer
- SoVarGen
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intrathecal
01
Overview
SVG301 (also known as SVG-301) is a first-in-class antisense oligonucleotide (ASO) designed to target and degrade BRAF mRNA transcripts. Developed by SoVarGen, a spin-out from the Korea Advanced Institute of Science and Technology (KAIST), SVG301 is administered intrathecally to bypass the blood-brain barrier and directly target the BRAF gene in the central nervous system. It is being developed for the treatment of pediatric brain tumors, specifically BRAF-mutant low-grade glioma (LGG) associated with intractable epilepsy. In preclinical studies, SVG301 has demonstrated the ability to reduce tumor size, alleviate epileptic seizures, and induce the reprogramming of BRAF-mutant tumor cells into functional, non-malignant oligodendrocytes.
- Other names
- BRAF antisense oligonucleotideBraf ASO
02
Targets
Beyond the preview
Go deeper on SVG301 (SoVarGen).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SVG301 (SoVarGen).